Cargando…

Cryopyrin associated periodic syndromes (CAPS): immunological characterization of knock-in mouse model to exploit novel approaches for the modulation of the NLRP3 inflammasome.

Detalles Bibliográficos
Autores principales:	Bertoni, A, Carta, S, Balza, E, Catellani, P, Pellecchia, C, Penco, F, Schena, F, Borghini, S, Trotta, ML, Pastorino, C, Ceccherini, I, Martini, A, Rubartelli, A, Gattorno, M, Chiesa, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600051/ http://dx.doi.org/10.1186/1546-0096-13-S1-P200

Ejemplares similares

PReS-FINAL-2324: PAPA syndrome clinical spectrum and IL-1Β release
por: Omenetti, A, et al.
Publicado: (2013)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
por: Bibalo, C, et al.
Publicado: (2011)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

B cells characterization in ADA2 Deficiency patients
por: Schena, F, et al.
Publicado: (2015)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

Recruitment of abundant NK cells to the PFAPA tonsils support the crucial role of innate immunity in pathogenesis of PFAPA syndrome
por: Chiesa, S, et al.
Publicado: (2015)

Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance
por: Balza, E, et al.
Publicado: (2016)

The RaDiCEA Project: cost of illness (COI) analysis applied to Cryopyrin Associated Periodic Syndromes (CAPS)
por: Della Casa Alberighi, O, et al.
Publicado: (2015)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

OR5-001 – Characterization of tonsil infiltration in PFAPA
por: Chiesa, S, et al.
Publicado: (2013)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

Cost-effectiveness analysis and prevention effects of ultra-orphan drugs for rare diseases: an in silico model applied to Cryopyrin Associated Periodic Syndromes (CAPS)
por: Trieste, L, et al.
Publicado: (2015)

Clinical Presentation and Pathogenesis of Cold-Induced Autoinflammatory Disease in a Family With Recurrence of an NLRP12 Mutation
por: Borghini, S, et al.
Publicado: (2011)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
por: Church, Leigh D, et al.
Publicado: (2008)

OR7-003 – MEFV genotype, IL1B and role of NLRP3 in FMF
por: Omenetti, A, et al.
Publicado: (2013)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

Different pattern of synthesis and secretion of IL-1beta in patients with CIAS-1 and TNFRSF1A mutations responding to IL-1 blockade
por: Lasigliè, D, et al.
Publicado: (2008)

Late onset of the cryopyrin-associated periodic syndrome (CAPS) associated with low level of somatic mosaicism in six patients
por: Rowczenio, D, et al.
Publicado: (2015)

Monogenic polyarteritis: the lesson of ADA2 deficiency
por: Caorsi, Roberta, et al.
Publicado: (2016)

Progressive waves of IL-1β release by primary human monocytes via sequential activation of vesicular and gasdermin D-mediated secretory pathways
por: Semino, Claudia, et al.
Publicado: (2018)

PW02-006 - PAPA syndrome clinical spectrum and IL1B release
por: Omenetti, A, et al.
Publicado: (2013)

Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity
por: Signa, Sara, et al.
Publicado: (2022)

Cryopyrin-associated periodic syndromes (CAPS): report on two cases (Muckle-Wells syndrome (MWS) and CINCA/NOMID)
por: Salugina, SO, et al.
Publicado: (2011)

PReS-FINAL-2241: Cases of cryopyrin-associated periodic syndromes (CAPS) in one single rheumatologic center of Russia
por: Salugina, SO, et al.
Publicado: (2013)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

Neurology of the Cryopyrin-Associated Periodic Feversyndrome
por: Parker, T, et al.
Publicado: (2015)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models
por: Balza, Enrica, et al.
Publicado: (2021)

Significance of I313V mutation of NLPR3 gene in two pediatric patients
por: Omenetti, A, et al.
Publicado: (2011)

Glyburide inhibits the Cryopyrin/Nalp3 inflammasome
por: Lamkanfi, Mohamed, et al.
Publicado: (2009)

Unified modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Gul, A, et al.
Publicado: (2015)

Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System
por: Keddie, Stephen, et al.
Publicado: (2018)

β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics
por: Kuemmerle-Deschner, J, et al.
Publicado: (2011)

The NALP3/Cryopyrin-Inflammasome Complex is Expressed in LPS-Induced Ocular Inflammation
por: González-Benítez, José F., et al.
Publicado: (2008)

French Amyloidosis CAPS study: AA Amyloidosis complicating cryopyrin-associated periodic syndrome: a study on 14 cases and review of 53 cases from literature
por: Georgin-Lavialle, S, et al.
Publicado: (2015)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_93ga27omnpk0tab2mpkko0a3fv